drugset / Trial / NCT06288360
Neoadjuvant Immunochemotherapy in PD-L1-negative LACC
Phase 2
Recruiting
40 enrolled
Tongji Hospital
Anhui Provincial Cancer Hospital · collabBeijing Friendship Hospital · collabCancer Hospital of Guangxi Medical University · collabGansu Provincial Maternal and Child Health Care Hospital · collabQilu Hospital of Shandong University · collabShengjing Hospital · collabSichuan Cancer Hospital and Research Institute · collabSouthwest Hospital, China · collabSun Yat-Sen Memorial Hospital of Sun Yat-Sen University · collabTianjin Medical University General Hospital · collabWest China Second University Hospital · collabWomen's Hospital School Of Medicine Zhejiang University · collabXiangya Hospital of Central South University · collabZhejiang Cancer Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a multicenter, prospective, single-arm, phase 2 clinical trial designed to evaluate the therapeutic efficacy of the NACI (neoadjuvant chemotherapy plus Camrelizumab) for PD-L1-negative locally advanced cervical cancer.
Timeline
- Start
- 2024-09-12
- Primary completion
- 2025-12-31
- Completion
- 2030-12-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Cisplatin | Other / unclassified | 75 mg/m2 | — |
| Subject | Cisplatin | Other / unclassified | 80 mg/m2 | — |
| Subject | Paclitaxel | Small molecule | 260 mg/m2 | — |